Effect of monthly administration of 40mg saccharated ferric oxide on hemoglobin variability and erythropoiesis resistance index in patients with hemodialysis

Effect of monthly administration of 40mg saccharated ferric oxide on hemoglobin variability and erythropoiesis resistance index in patients with hemodialysis - Hb variability and ERI by monthly administration of iron in HD patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026308

Enrollment

300

Registered

2021-03-31

Start date

2017-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

end stage renal disease

Interventions

monthly iron administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Clinically stable HD patients with renal anemia more than 1 year 2.Written informed consent was obtained

Exclusion criteria

Exclusion criteria: 1. Iron deficiency 2. Vitamin B12 and/or folate deficiency 3. Unstable iron metabolism 4. Drug allergy 5. Written informed consent was not obtained

Design outcomes

Primary

Measure	Time frame
Hemoglobin variability	—

Secondary

Measure	Time frame
1)erythropoiesis resistance index 2)Iron deficiency 3)iron exccess	—

Countries

Japan

Contacts

Public ContactTatsuo Tsukamoto

Kitano Hospital, The Tazuke Kofukai Medical Research Institute Neohrology & Dialysis

t-tsukamoto@kitano-hp.or.jp06-6312-8824

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026